London, the capital of England and the United Kingdom, is a 21st-century city with history stretching back to Roman times. At its centre stand the imposing Houses of Parliament, the iconic ‘Big Ben’ clock tower and Westminster Abbey, site of British monarch coronations. Across the Thames River, the London Eye observation wheel provides panoramic views of the South Bank cultural complex, and the entire city. ― Google

During the past decade, University College London conducted 98 clinical trials. In the 10-year time frame, 98 clinical trials started and 29 clinical trials were completed, i.e. on average, 29.6% percent of trials that started reached the finish line to date. In the past 5 years, 45 clinical trials started and 23 clinical trials were completed. i.e. 51.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University College London" #1 sponsor was "University College, London" with 55 trials, followed by "Gilead Sciences" with 8 trials sponsored, "Agios Pharmaceuticals, Inc." with 5 trials sponsored, "Alector Inc." with 5 trials sponsored and "Bioverativ, a Sanofi company" with 5 trials sponsored. Other sponsors include 61 different institutions and companies that sponsored additional 65 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University College London" #1 collaborator was "University College, London" with 11 trials as a collaborator, "Cancer Research UK" with 5 trials as a collaborator, "National Institute for Health Research, United Kingdom" with 5 trials as a collaborator, "Wellcome Trust" with 5 trials as a collaborator and "Medical Research Council" with 4 trials as a collaborator. Other collaborators include 166 different institutions and companies that were collaborators in the rest 153 trials.

According to Clinical.Site data, the most researched conditions in "University College London" are "Heart Failure" (8 trials), "Stroke" (8 trials), "Myocardial Infarction" (7 trials), "Abdominal Aortic Aneurysm" (5 trials) and "Chronic Lymphocytic Leukemia" (5 trials). Many other conditions were trialed in "University College London" in a lesser frequency.

Most popular intervention types in "University College London" are "Drug" (67 trials), "Other" (30 trials), "Device" (10 trials), "Procedure" (9 trials) and "Behavioral" (7 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (22 trials), "AG-348" (3 trials), "AL001" (3 trials), "Idelalisib" (3 trials) and "Rituximab" (3 trials). Other intervention names were less common.

The vast majority of trials in "University College London" are 127 trials for "All" genders, 9 trials for "Female" genders and 5 trials for "Male" genders.

Currently, there are 42 active trials in "University College London". 4 are not yet recruiting, 23 are recruiting, 13 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 66 completed trials in University College London, 1 suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in University College London, 14 "Phase 1" clinical trials were conducted, 30 "Phase 2" clinical trials and 35 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 34 trials that are defined as “Not Applicable".

University College London has several departments that took part in Clinical trials: "UCL Institute of Neurology" - 19 trials, "Cancer Research UK and University College London Cancer Trials Centre" - 11 trials, "Queen Square Centre for Neuromuscular Diseases" - 11 trials, "Medical Research Council Clinical Trials Unit" - 11 trials, "Dubowitz Neuromuscular Centre" - 8 trials, "Leonard Wolfson Experimental Neurology Centre" - 7 trials, "UCL Cancer Institute" - 3 trials, "Eastman Dental Institute, University College London" - 5 trials, "UCL Center for Nephrology" - 2 trials, "Royal Free Hospital, Institute of Liver and Digestive Disease" - 2 trials, "Eastman Clinical Investigation Centre" - 2 trials, "UCL Queen Square Institute of Neurology" - 2 trials, "University College London, Department of Haematology" - 2 trials, "Clinical Psychopharmacology Unit" - 2 trials